ReviewCurrent osteoporosis reports2007
Medication-induced osteoporosis.
Review in Current osteoporosis reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Pooled it
- Vitamin D supplementation and falls in residential aged care: A longitudinal multisite cohort study.Bone reports · 2024Article
- Cortical bone quality affectations and their strength impact analysis using holographic interferometry.Biomedical optics express · 2018Article
- Skeletal Implications of Chronic Obstructive Pulmonary Disease.Current osteoporosis reports · 2016Review
- Adherence to treatment with selective serotonin reuptake inhibitors and the risk for fractures and bone loss: a population-based cohort study.CNS drugs · 2012Article
- Walk on the sunny side of life--epidemiology of hypovitaminosis D and mental health in elderly nursing home residents.The journal of nutrition, health & aging · 2012Article
- Diseases affecting bone quality: beyond osteoporosis.Clinical orthopaedics and related research · 2011Review
- The genetics of bone loss: challenges and prospects.The Journal of clinical endocrinology and metabolism · 2011Review
- Simvastatin attenuates TNF-alpha-induced growth inhibition and apoptosis in murine osteoblastic MC3T3-E1 cells.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010Article
- Bone: serotonin, leptin and the central control of bone remodeling.Nature reviews. Rheumatology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, a condition of low bone mass and microarchitectural deterioration, results in fractures with minimal trauma. Secondary osteoporosis is defined as bone loss resulting from either specific clinical disorders or medications. Some medications that can induce osteoporosis are discussed. Specifically, this article reviews the pathogenesis of glucocorticoid-induced bone loss and demonstrates the means to successfully manage the condition with a combination of calcium and vitamin D supplementation and, depending on the severity of the bone loss, bisphosphonates or parathyroid hormone. In addition, the pathophysiology of bone loss from aromatase inhibitors in women, gonadotropin-releasing hormone agonists in men, anticonvulsant medications, and proton pump inhibitors is outlined. Finally, this review offers suggestions on evaluation and management of bone health in individuals treated with these medications for prolonged times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.